Encephalopathy – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Encephalopathy – Pipeline Review, H2 2016’, provides an overview of the Encephalopathy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Encephalopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Encephalopathy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Encephalopathy

The report reviews pipeline therapeutics for Encephalopathy by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Encephalopathy therapeutics and enlists all their major and minor projects

The report assesses Encephalopathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Encephalopathy

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Encephalopathy

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Encephalopathy pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Celgene Corp

Chiesi Farmaceutici SpA

Fera Pharmaceuticals LLC

GW Pharmaceuticals Plc

JS Genetics Inc

ProThera Biologics Inc

SciFluor Life Sciences LLC

Turing Pharmaceuticals AG

Zambon Company SpA

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Encephalopathy Overview 7

Therapeutics Development 8

Pipeline Products for Encephalopathy - Overview 8

Pipeline Products for Encephalopathy - Comparative Analysis 9

Encephalopathy - Therapeutics under Development by Companies 10

Encephalopathy - Therapeutics under Investigation by Universities/Institutes 11

Encephalopathy - Pipeline Products Glance 12

Clinical Stage Products 12

Early Stage Products 13

Encephalopathy - Products under Development by Companies 14

Encephalopathy - Products under Investigation by Universities/Institutes 15

Encephalopathy - Companies Involved in Therapeutics Development 16

Celgene Corp 16

Chiesi Farmaceutici SpA 17

Fera Pharmaceuticals LLC 18

GW Pharmaceuticals Plc 19

JS Genetics Inc 20

ProThera Biologics Inc 21

SciFluor Life Sciences LLC 22

Turing Pharmaceuticals AG 23

Zambon Company SpA 24

Encephalopathy - Therapeutics Assessment 25

Assessment by Monotherapy Products 25

Assessment by Target 26

Assessment by Mechanism of Action 28

Assessment by Route of Administration 30

Assessment by Molecule Type 32

Drug Profiles 34

Alda-1 - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

diazoxide - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

GWP-42003 - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

melatonin - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

ORP-006 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

phenobarbitol sodium - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

Proteins for Hypoxic-Ischemic Brain Injury - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

SF-0034 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

Stem Cell Therapy for Encephalopathy and Periventricular Leukomalacia - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

Stem Cell Therapy for Hematological Malignancies, Hypoxic-ischemic Encephalopathy and Solid Tumor - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

TRP-005 - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

TRP-601 - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

TUR-004 - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

ZP-053 - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

Encephalopathy - Product Development Milestones 50

Featured News & Press Releases 50

Nov 16, 2015: Turing Initiates Dosing in Phase I Clinical Trial of TUR 004 for Epileptic Encephalopathies 50

Oct 23, 2015: Turing Pharmaceuticals Announces FDA Acceptance of Investigational New Drug Application and Fast Track Designation for TUR-004 50

Aug 06, 2015: GW Pharmaceuticals Receives FDA Fast Track and EMA Orphan Designations for Intravenous Cannabidiol in the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy 51

Apr 24, 2015: GW Pharmaceuticals Receives Orphan Drug Designation From FDA for Cannabidiol for the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy 51

Appendix 53

Methodology 53

Coverage 53

Secondary Research 53

Primary Research 53

Expert Panel Validation 53

Contact Us 53

Disclaimer 54

List of Tables

List of Tables

Number of Products under Development for Encephalopathy, H2 2016 8

Number of Products under Development for Encephalopathy – Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Number of Products under Investigation by Universities/Institutes, H2 2016 11

Comparative Analysis by Clinical Stage Development, H2 2016 12

Comparative Analysis by Early Stage Development, H2 2016 13

Products under Development by Companies, H2 2016 14

Products under Investigation by Universities/Institutes, H2 2016 15

Encephalopathy – Pipeline by Celgene Corp, H2 2016 16

Encephalopathy – Pipeline by Chiesi Farmaceutici SpA, H2 2016 17

Encephalopathy – Pipeline by Fera Pharmaceuticals LLC, H2 2016 18

Encephalopathy – Pipeline by GW Pharmaceuticals Plc, H2 2016 19

Encephalopathy – Pipeline by JS Genetics Inc, H2 2016 20

Encephalopathy – Pipeline by ProThera Biologics Inc, H2 2016 21

Encephalopathy – Pipeline by SciFluor Life Sciences LLC, H2 2016 22

Encephalopathy – Pipeline by Turing Pharmaceuticals AG, H2 2016 23

Encephalopathy – Pipeline by Zambon Company SpA, H2 2016 24

Assessment by Monotherapy Products, H2 2016 25

Number of Products by Stage and Target, H2 2016 27

Number of Products by Stage and Mechanism of Action, H2 2016 29

Number of Products by Stage and Route of Administration, H2 2016 31

Number of Products by Stage and Molecule Type, H2 2016 33

List of Figures

List of Figures

Number of Products under Development for Encephalopathy, H2 2016 8

Number of Products under Development for Encephalopathy – Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 13

Assessment by Monotherapy Products, H2 2016 25

Number of Products by Targets, H2 2016 26

Number of Products by Stage and Targets, H2 2016 26

Number of Products by Mechanism of Actions, H2 2016 28

Number of Products by Stage and Mechanism of Actions, H2 2016 28

Number of Products by Routes of Administration, H2 2016 30

Number of Products by Stage and Routes of Administration, H2 2016 30

Number of Products by Molecule Types, H2 2016 32

Number of Products by Stage and Molecule Types, H2 2016 32

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports